Daraxonrasib pill shows tumour elimination in pancreatic cancer trial
Published 16 h ago1 sourceEvidence: Reported
Phase trial data for the KRAS-targeting pill daraxonrasib shows tumor shrinkage in nearly all 61 advanced pancreatic cancer patients, with undetectable disease in roughly 8%. This is a first-in-class oral therapy for a notoriously refractory cancer, though durability and survival benefit remain unproven at this early readout.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Entities
Published 16 h ago1 sourceEvidence: Reported
Published 1 d ago1 sourceEvidence: Reported
Published 6 h ago2 sourcesEvidence: Reported
Published 1 d ago2 sourcesEvidence: Reported
Published 8 h ago1 sourceEvidence: Reported
Published 4 h ago2 sourcesEvidence: Reported
Published 3 h ago1 sourceEvidence: Reported
Published 17 h ago1 sourceEvidence: Reported